Midane (Cyproterone Acetate, Ethinylestradiol)

Ethinylestradiol suppresses the hypothalamic‑pituitary‑gonadal axis, reducing the release of gonadotropins and thereby preventing ovulation. Cyproterone acetate adds anti‑androgen activity by blocking androgen receptors and further inhibiting gonadotropin secretion, which together provide contraceptive efficacy and improve androgen‑related dermatologic conditions.

The dosing regimen for Midane is determined by the prescribing clinician based on the product label and individual patient factors. Typically, the medication is taken once daily for a defined cycle, but the exact schedule and duration should be confirmed with the healthcare provider.

Midane is classified as Pregnancy Category X, meaning it must not be used during pregnancy because it can cause fetal harm. It is also generally not recommended for breastfeeding women, as the hormones can be excreted in breast milk and may affect the infant.

To order Midane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Midane offers the same contraceptive efficacy as other combined estrogen‑progestogen pills but includes cyproterone acetate, which provides additional anti‑androgenic activity. This makes it particularly useful for patients who also need treatment for acne or hirsutism, a benefit not shared by all standard combined oral contraceptives.

Midane tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Midane is taken orally as a tablet, usually once each day at the same time. It can be taken with or without food, but consistency with respect to meals helps maintain stable absorption. Patients should follow the schedule prescribed by their healthcare professional.

The most serious adverse events associated with Midane include venous thromboembolism (blood clots), hepatic dysfunction (liver enzyme abnormalities or jaundice), and hypertensive crises. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, severe abdominal pain, yellowing of the skin or eyes, or a sudden, severe increase in blood pressure.

Midane should not be used by women who are pregnant, have a known clotting disorder, have a history of stroke or myocardial infarction, are over 35 years old and smoke heavily, have active liver disease, or have known hypersensitivity to any component of the formulation.